Similarly, CD16-CD56 on NKT (OR = 0.978, 95% CI 0.969–0.986, P = 2.35e − 05), CD62L on monocyte (OR = 0.981, 95% CI 0.971–0.990, P = 2.67e − 03), CD127 on CD28- CD8br (OR = 0.976, 95% CI 0.962–0.990, P = 1.32e − 02), CD25 on CD39 + activated Treg (OR = 0.973, 95% CI 0.956–0.989, P = 2.59e − 02), and CD25 on activated Treg (OR = 0.991, 95% CI 0.985–0.997, P = 3.45e − 02) also indicated a significant negative causal impact on AAA risk. The gene discussed is SELL; the disease is triple-A syndrome.